Evaxion welcomes Thomas Bogenrieder, M.D., Ph.D, as Chief Medical Officer.
With over 15+ years in oncology drug development and the global life sciences industry, Dr. Bogenrieder brings invaluable experience to the team. His academic qualifications include a Ph.D. degree, from the University of Utrecht, for his work on Clinico-pathological and Molecular Aspects of Cutaneous Melanoma, and over 50 peer-reviewed journal articles.
Having previously worked as a global clinical development leader at Boehringer-Ingelheim in Vienna, he oversaw clinical programs from their inception, and focused primarily on early oncology therapeutic programs, strategy and development. There, he was also responsible for a range of in-depth evaluations of in-licensing opportunities, including clinical trials and proof-of-concept research.
Prior to this, Dr. Bogenrieder worked at GlaxoSmithKline as Medical Advisor and European Medical Director Oncology for pipeline compounds. At GSK, he managed several NMEs that lead to successful multi-billion dollar marketed pharmaceutical products. Dr. Bogenrieder’s knowledge and extensive experience in scientific-medical affairs, R&D and general management of cancer vaccines and pharmaceuticals will help guide Evaxion’s growth as the company enters clinical trials in 2019.